Abstracts

Rationale: Restless legs syndrome (RLS) is a common neurological movement disorder occurring in approximately 10% of the general population. Epilepsy is also a common neurological disorder with significant associated morbidity and impact on quality of life. We evaluated the efficacy of eslicarbazepine (ESL) treatment in patients with focal epilepsy who associated RLS. Methods: All epilepsy patients seen in the outpatient clinic were screened for sleep movement disorders from January to March 2019. Seven patients met AAN RLS criteria and ILAE criteria for focal epilepsy. Clinical profiles of epilepsy, RLS, other comorbidities and laboratory data were collected. Furthermore, patients with obstructive sleep apnea or a definite cause of secondary restless legs syndrome were excluded from the study. Results: We included 7 patients (females 4, males 3). Mean age was 50.57 year-old. Three were pharmacorresistant at baseline. Three of them with clinical history of ferropenic anemia but normal ferritin levels at baseline. The initial mean dose was 457.14 mg (just 1 patient with a 800 mg dose). Five were on monotherapy for epilepsy control. Mean day with RLS symptons at week was 5.14 at baseline and 0.57 three months later. Six patients reported improvement of symptoms. All of them were previously treated for RLS (mean number of treatments 2.28) being the most frequent pramipexole (6) and rotigotine (3). ESL was generally well-tolerated, adverse events were mild and not frequent (2 patients, dizziness). Conclusions: Eslicarbacepine could be effective for the treatment of restless legs syndrome and should be considered when focal-epilepsy and RLS is associated Funding: No funding